- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05159245
표적 항암제에 대한 환자 접근성을 촉진하기 위한 핀란드 국가 연구 (FINPROVE)
알려진 분자 프로파일을 가진 진행성 암 치료의 효능을 결정하기 위해 표적 항암제에 대한 환자 접근을 촉진하기 위한 핀란드 국립 연구
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
연구 개요
상태
상세 설명
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Tanja Juslin
- 전화번호: +358405597415
- 이메일: tanja.juslin@hus.fi
연구 장소
-
-
-
Kuopio, 핀란드
- 모병
- Kuopio University Hospital
-
연락하다:
- Okko Kääriäinen, MD
-
Oulu, 핀란드
- 모병
- Oulu University Hospital OYS Cancer Center
-
연락하다:
- Sanna Iivanainen, MD. PhD.
-
Tampere, 핀란드
- 모병
- Tampere University Hospital Department of Oncology
-
연락하다:
- Minna Tanner, MD, PhD
-
-
Southwest Finland
-
Turku, Southwest Finland, 핀란드
- 모병
- Turku University Hospital Cancer Centre
-
연락하다:
- Erika Alanne, MD, PhD
-
-
Uusimaa
-
Helsinki, Uusimaa, 핀란드, 00029
- 모병
- Helsinki University Hospital Comprehensive Cancer Center
-
연락하다:
- Tanja Juslin
-
수석 연구원:
- Katriina Jalkanen, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
-
ECOG performance status 0-2
-
Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:
- Absolute neutrophil count ≥ 1.5 x 109/l
- Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
- Platelets > 75 x 109/l (not applicable for hematological patients)
- Total bilirubin < 1.5 x ULN
- AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
-
Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.
-
Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.
-
Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.
-
A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.
-
Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.
Exclusion Criteria:
-
Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.
-
Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:
- Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
- Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
-
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
-
Patient is pregnant or nursing.
-
Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible
-
Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible
-
Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Alectinib
For patients with a molecular tumor profile that can potentially be targeted by alectinib. |
ALK
다른 이름들:
|
|
실험적: Cobimetinib
For patients with a molecular tumor profile that can potentially be targeted by cobimetinib. |
MEK1, MEK2
다른 이름들:
|
|
실험적: Vismodegib
For patients with a molecular tumor profile that can potentially be targeted by vismodegib. |
Hedgehog
다른 이름들:
|
|
실험적: Trastuzumab+Pertuzumab
For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination. |
HER2
다른 이름들:
|
|
실험적: Entrectinib
For patients with a molecular tumor profile that can potentially be targeted by entrectinib. |
NTRK/ ROS1, ALK
다른 이름들:
|
|
실험적: Atezolizumab
For patients with a molecular tumor profile that can potentially be targeted by atezolizumab. |
PD-L1
다른 이름들:
|
|
실험적: Vemurafenib
For patients with a molecular tumor profile that can potentially be targeted by vemurafenib. |
BRAF V600
다른 이름들:
|
|
실험적: Regorafenib
For patients with a molecular tumor profile that can potentially be targeted by regorafenib. |
KIT/BRAF, RET
다른 이름들:
|
|
실험적: Apalutamide
For patients with a molecular tumor profile that can potentially be targeted by apalutamide. |
AR
다른 이름들:
|
|
실험적: Abemaciclib
For patients with a molecular tumor profile that can potentially be targeted by abemaciclib. |
CDK4/6
다른 이름들:
|
|
실험적: Tepotinib
For patients with a molecular tumor profile that can potentially be targeted by tepotinib. |
MET ex14
다른 이름들:
|
|
실험적: Dabrafenib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib. |
RAF
다른 이름들:
|
|
실험적: Trametinib
For patients with a molecular tumor profile that can potentially be targeted by trametinib. |
MEK1, MEK2
다른 이름들:
|
|
실험적: Dabrafenib+Trametinib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination. |
RAF, MEK1, MEK2
다른 이름들:
|
|
실험적: Pemigatinib
For patients with a molecular tumor profile that can potentially be targeted by pemigatinib. |
FGFR2
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease control rate
기간: 16 weeks
|
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD) |
16 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Duration of treatment
기간: 5 years
|
Time on drug |
5 years
|
|
Adverse Events
기간: 5 years
|
Treatment-related grade ≥3 and serious adverse events |
5 years
|
|
Overall response
기간: 5 years
|
Best overall response (defined as patients by CR, PR, SD) |
5 years
|
|
PFS
기간: 5 years
|
Progression free survival |
5 years
|
|
OS
기간: 5 years
|
Overall survival |
5 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- FINPROVE
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Investigators plan to share the clinical study report.
IPD 공유 기간
2026-2027
IPD 공유 액세스 기준
Will be made available through European regulatory CTIS programme.
IPD 공유 지원 정보 유형
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .